TrialTranslational psychiatry2022

Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.

Colin Sauder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.